These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 3573950)

  • 21. Leprosy treatment in Nepal with multidrug regimens.
    Birch MC
    Lepr Rev; 1984 Sep; 55(3):255-64. PubMed ID: 6492986
    [No Abstract]   [Full Text] [Related]  

  • 22. Relapse following fixed duration treatment for multibacillary leprosy.
    Wkly Epidemiol Rec; 1994 Oct; 69(41):301-2. PubMed ID: 7986699
    [No Abstract]   [Full Text] [Related]  

  • 23. The impact of MDT implementation in the Tanzania National TB-Leprosy Programme.
    Chum HJ
    Lepr Rev; 1986; 57 Suppl 3():63-6. PubMed ID: 3573963
    [No Abstract]   [Full Text] [Related]  

  • 24. Implementation of tests for monitoring drug compliance of leprosy out-patients under multi-drug therapy.
    Balakrishnan S; Kumar A; Rao BR; Patro TP
    Indian J Lepr; 1986; 58(4):555-9. PubMed ID: 3572097
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Diagnosis and impact of neuropathic pain in leprosy patients in Nepal after completion of multidrug therapy.
    Toh HS; Maharjan J; Thapa R; Neupane KD; Shah M; Baral S; Hagge DA; Napit IB; Lockwood DNJ
    PLoS Negl Trop Dis; 2018 Jul; 12(7):e0006610. PubMed ID: 29965957
    [TBL] [Abstract][Full Text] [Related]  

  • 26. International Leprosy Congress 2002--lessons learned.
    Smith WC
    Lepr Rev; 2003 Mar; 74(1):7-10. PubMed ID: 12669927
    [No Abstract]   [Full Text] [Related]  

  • 27. A retrospective study of the effect of modified multi-drug therapy in Nepali leprosy patients following the development of adverse effects due to dapsone.
    Sapkota BR; Shrestha K; Pandey B; Walker SL
    Lepr Rev; 2008 Dec; 79(4):425-8. PubMed ID: 19274989
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Are 18 doses of WHO/MDT sufficient for multibacillary leprosy; results of a trial in Malawi.
    Pönnighaus JM; Boerrigter G
    Int J Lepr Other Mycobact Dis; 1995 Mar; 63(1):1-7. PubMed ID: 7730703
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Experience with multidrug therapy in Sierra Leone: clinical, operational and managerial analysis.
    Rangaraj M; Rangaraj J
    Lepr Rev; 1986; 57 Suppl 3():77-91. PubMed ID: 3573965
    [No Abstract]   [Full Text] [Related]  

  • 30. Multidrug therapy in paucibacillary leprosy.
    Jopling WH
    Lepr Rev; 1990 Dec; 61(4):391. PubMed ID: 2280662
    [No Abstract]   [Full Text] [Related]  

  • 31. Multidrug treatment of leprosy--practical application in Nepal.
    Samuel NM; Samuel S; Nakami N; Murmu R
    Lepr Rev; 1984 Sep; 55(3):265-72. PubMed ID: 6492987
    [No Abstract]   [Full Text] [Related]  

  • 32. [Antileprosy polychemotherapy in the member states of the OCCGE: a decade of implementation (1983-19930). The National Coordinators of the Leprosy Program of the 8 states of the OCCGE].
    Tiendrebeogo A; Blanc L; Sylla PM
    Acta Leprol; 1995; 9(3):139-47. PubMed ID: 7631585
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Duration of MDT for paucibacillary leprosy.
    Ramu G
    Indian J Lepr; 1992; 64(1):1-7. PubMed ID: 1290484
    [No Abstract]   [Full Text] [Related]  

  • 34. Shortening duration of treatment of multibacillary leprosy. Action Programme for the Elimination of Leprosy, WHO.
    Indian J Lepr; 1997; 69(3):267-70. PubMed ID: 9394176
    [No Abstract]   [Full Text] [Related]  

  • 35. Recent developments in leprosy control.
    Noordeen SK
    Trop Geogr Med; 1991 Jul; 43(3):S5-12. PubMed ID: 1687771
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Drug resistance and multi-drug therapy in leprosy.
    Chatterjee BR
    Lepr India; 1982 Jul; 54(3):402-11. PubMed ID: 6757576
    [No Abstract]   [Full Text] [Related]  

  • 37. Implementation of multidrug therapy for leprosy control programmes.
    Porichha D
    Lepr Rev; 1990 Dec; 61(4):392-3. PubMed ID: 2280664
    [No Abstract]   [Full Text] [Related]  

  • 38. [Experiences in implementing WHO/MDT in the south west of Bangladesh].
    Ishida Y; Pecorini L; Guglielmelli E
    Nihon Hansenbyo Gakkai Zasshi; 1998 Jul; 67(2):329-43. PubMed ID: 9785848
    [No Abstract]   [Full Text] [Related]  

  • 39. Parallel assessment of 24 monthly doses of rifampin, ofloxacin, and minocycline versus two years of World Health Organization multi-drug therapy for multi-bacillary leprosy.
    Villahermosa LG; Fajardo TT; Abalos RM; Cellona RV; Balagon MV; Dela Cruz EC; Tan EV; Walsh GP; Walsh DS
    Am J Trop Med Hyg; 2004 Feb; 70(2):197-200. PubMed ID: 14993633
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Non-adherence to leprosy treatment in Western Sudan; the people behind the numbers.
    Coebergh JA; Buddingh H
    Lepr Rev; 2004 Dec; 75(4):404. PubMed ID: 15682977
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.